Entero Therapeutics, Inc. (ENTO)
NASDAQ: ENTO · Real-Time Price · USD
0.417
+0.017 (4.20%)
Oct 10, 2024, 1:48 PM EDT - Market open

Company Description

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases.

The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.

It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients.

The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024.

Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.

Entero Therapeutics, Inc.
Entero Therapeutics logo
Country United States
Founded 2014
IPO Date Oct 11, 2016
Industry Biotechnology
Sector Healthcare
Employees 9
CEO James Sapirstein

Contact Details

Address:
777 Yamato Road, Suite 502
Boca Raton, Florida 33431
United States
Phone 561 589 7020
Website enterothera.com

Stock Details

Ticker Symbol ENTO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001604191
ISIN Number US33749P4081
Employer ID 46-4993860
SIC Code 2834

Key Executives

Name Position
James R. Sapirstein M.B.A., R.Ph. Chief Executive Officer and Chairman
Sarah Romano CPA Chief Financial Officer
Amy Chandler-Skerkis Vice President of Regulatory Affairs, QA and Compliance
Martin Krusin M.B.A. Senior Vice President of Corporate Development
Jennifer A. Sealey-Voyksner Ph.D. Senior Vice President for Research and Development

Latest SEC Filings

Date Type Title
Sep 11, 2024 8-K Current Report
Sep 10, 2024 8-K Current Report
Sep 3, 2024 8-K Current Report
Aug 29, 2024 8-K Current Report
Aug 23, 2024 8-K Current Report
Aug 22, 2024 8-K Current Report
Aug 15, 2024 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
Aug 15, 2024 8-K Current Report
Aug 7, 2024 8-K Current Report
Jul 31, 2024 8-K Current Report